Cholesterol and Hyperlipidemia: The Silent Accumulation That’s Quietly Rewriting Your Cardiovascular Future

What your lipid numbers actually tell you, why standard panels miss more than they catch, and what a complete picture looks like.

By the Numbers

• ~94 million U.S. adults with total cholesterol above 200 mg/dL
• 1 in 5 People with elevated Lp(a), a genetic cardiovascular risk factor most have never been tested for
• ~800,000 Heart attacks in the United States each year, most in people with known or discoverable risk
• < 25% Of U.S. adults with high cholesterol who have it under control

What Is Cholesterol, Actually?

Cholesterol isn’t the enemy it’s made out to be. It’s a waxy, fat-like substance your liver makes, and your body needs it. It’s part of every cell wall, helps make hormones like testosterone and cortisol, and helps you make vitamin D and digest fat. You can’t live without it. In fact, most of the cholesterol in your body isn’t from food at all. Your liver makes the majority of it, which is a big reason why diet alone often isn’t enough to fully control a genetic tendency toward high cholesterol.

The problem isn’t cholesterol itself. It’s what happens when too much of certain cholesterol-carrying particles build up in your artery walls. This triggers inflammation and slowly narrows your blood vessels, often over decades, without you feeling a thing. Think of it less like a single event and more like sediment slowly building up in a pipe: invisible from the outside, but gradually narrowing the space blood has to flow through.

Cholesterol travels through your blood inside carriers called lipoproteins. LDL (low-density lipoprotein) carries cholesterol out to the rest of the body. HDL (high-density lipoprotein) carries it back to the liver to be removed. When LDL is high, HDL is low, or the balance shifts the wrong way, your cardiovascular risk goes up.

Here’s something most patients never hear: not all LDL particles are alike. The number of particles matters as much as how much cholesterol they carry. Two people can have the same LDL number and face very different risk, for reasons a standard lipid panel doesn’t show. It’s a bit like comparing two delivery trucks: one carrying a light load and one carrying a heavy load can look the same size from the outside, but the amount they’re actually delivering to your arteries is different.

Triglycerides are the third piece: stored fat, built from the fat and extra calories you eat, especially refined carbs and sugar. High triglycerides rarely show up alone. They usually travel with low HDL, rising blood sugar, and higher cardiovascular risk.

This is why hyperlipidemia, the medical term for abnormal blood fat levels, is worth understanding well. Not every elevated number needs a prescription. But the right numbers, read in context, tell you where your heart health is headed, and give you something to act on.

That story starts at your annual physical.

The Numbers: What Do They Mean?

A standard lipid panel measures four things: total cholesterol, LDL, HDL, and triglycerides. That’s what most labs report. It’s a good starting point. For many patients, it’s not the whole story.

The Standard Panel, Explained

LDL cholesterol is the main treatment target. A level that’s fine for a healthy 30-year-old isn’t fine for someone with diabetes, high blood pressure, or a prior heart event.

HDL cholesterol is often called “good” cholesterol. Higher levels tend to protect you. Men below 40 mg/dL and women below 50 mg/dL are at higher risk. But more isn’t always better. Very high HDL doesn’t guarantee extra protection.

Triglycerides below 150 mg/dL are normal, 150-199 is borderline-high, 200-499 is high, and above 500 the risk of acute pancreatitis becomes real.

Total cholesterol is the least useful number alone. A high total driven by high HDL can be fine. Context matters more than the single number.

Beyond the Standard Panel

Non-HDL cholesterol is total cholesterol minus HDL. It captures every artery-damaging particle at once (LDL, VLDL, IDL), predicts risk better than LDL alone, and doesn’t require fasting. Target: under 130 mg/dL for lower-risk patients, under 100 mg/dL for higher-risk.

Apolipoprotein B (ApoB) is a protein on every artery-damaging particle, one copy per particle. That makes ApoB a direct count of dangerous particles, not just their cholesterol content. In most large studies it predicts heart events better than LDL, especially with metabolic syndrome, diabetes, or high triglycerides. Normal LDL with high ApoB means more dangerous particles than the LDL number suggests.

Lipoprotein(a), or Lp(a), is a risk factor most patients have never heard of. It gets its own section below.

The triglyceride-to-HDL ratio is an underused clue to insulin resistance. A ratio above 3.0 (mg/dL) points to more small, dense LDL particles, the kind that get into artery walls more easily. Combined with rising blood sugar or extra belly fat, it’s a strong signal of the insulin-resistance pattern.

Diagnostic Categories and Lipid Targets

Marker	Optimal	Borderline / At-Risk	Abnormal
LDL-C (mg/dL)	< 100	100–129	130–159 borderline high; 160+ high
HDL-C (mg/dL)	> 60 (protective)	40–59 (men); 50–59 (women)	< 40 (men); < 50 (women)
Triglycerides (mg/dL)	< 150	150–199	200–499 high; 500+ very high
Non-HDL-C (mg/dL)	< 130	130–159	160+
ApoB (mg/dL)	< 90	90–109	110+
Total Cholesterol (mg/dL)	< 200	200–239	240+
TG/HDL Ratio	< 2.0	2.0–3.0	> 3.0

Targets shift based on your overall cardiovascular risk. Patients at high or very high risk (established heart disease, diabetes, familial hypercholesterolemia) need tighter targets across the board.

A standard lipid panel catches four of these seven data points. It often misses risk in patients with a near-normal LDL but a high ApoB, an insulin-resistance pattern, or high Lp(a). At Altitude, we extend testing when the picture calls for it, not to add tests for their own sake, but to catch risk the standard panel can’t see.

The Borderline Zone: Not Low-Risk, Not Diagnosed

The most overlooked spot in heart health sits just outside the treatment threshold, close enough to look fine but not actually safe. Millions of patients land here, get a quick reassurance, and don’t think about it again for years.

An LDL between 100 and 129 mg/dL is often called “near optimal.” Near optimal for whom, though? For a 55-year-old with type 2 diabetes, high blood pressure, and a family history of early heart attacks, an LDL of 115 mg/dL is not reassuring. Risk isn’t about the number alone. It’s about the number in context.

A high Lp(a) can push someone with otherwise unremarkable lipids into a much higher risk category. A TG/HDL ratio above 3.0, especially with rising blood sugar, signals a dangerous particle pattern that LDL alone won’t show. These patients often look completely fine on a standard panel.

This borderline zone is your best window for action. Lifestyle changes work best here, before full hyperlipidemia sets in and long before a heart attack forces the issue. Arterial damage builds up well before you cross any official threshold.

Why “I Feel Fine” Doesn’t Mean You’re Fine

The absence of symptoms is not reassurance. Hyperlipidemia does its most dangerous work silently, across decades, inside arterial walls you cannot feel.

High cholesterol causes no symptoms. No fatigue, no chest pressure, no warning sign that would send most people to get checked. For most patients, the first symptom is the event itself: a heart attack, a stroke, a leg that suddenly loses circulation.

Atherosclerosis builds slowly, over years. LDL particles get damaged, work into the artery wall, and trigger an immune response that pulls in cells forming a plaque. These plaques narrow the artery, cut blood flow, and can rupture. A ruptured plaque triggers a clot. A clot in a heart artery is a heart attack. A clot in a brain artery is a stroke.

Studies of young adults’ arteries have found early signs of atherosclerosis in people still in their 20s. What happens to your arteries in early adulthood shapes your risk for decades.

“I feel fine” isn’t useful medical information. It just means this disease hasn’t given you a symptom yet. The only way to know where you stand is the right numbers, in context, with the right tests.

What Drives Cholesterol Up

Hyperlipidemia isn’t one disease with one cause. Most patients have several things going on at once, which is why fixing just one usually isn’t enough.

Diet. Saturated fat raises LDL by slowing how fast your liver clears LDL particles out of the blood. Trans fats are worse, though largely gone from the U.S. food supply now. Refined carbs and added sugar raise triglycerides by pushing your liver to produce more of the particles that carry them. How much your diet affects your cholesterol depends heavily on genetics: some people react strongly to saturated fat, others barely react at all. That’s part of why two people can eat similarly and end up with very different numbers.

Genetics. Familial hypercholesterolemia (FH) affects about 1 in 250 people and is badly underdiagnosed. It causes LDL levels of 190 mg/dL or higher from birth, caused by a faulty LDL receptor that can’t clear cholesterol from the blood efficiently. It carries much higher cardiovascular risk than average and usually needs treatment starting in young adulthood. It’s passed down from just one parent, it’s treatable, and most people who have it don’t know it.

Insulin resistance. This pattern looks different from typical high cholesterol: high triglycerides, low HDL, and a lot of small, dense LDL particles, often with an LDL number that looks perfectly fine on paper. It’s driven by belly fat, inactivity, and eating patterns that keep insulin chronically elevated, and it’s one of the most commonly missed drivers because the standard panel doesn’t flag it.

Thyroid disease. An underactive thyroid slows how fast your liver clears LDL, and it’s one of the first things we check when LDL rises unexpectedly, especially alongside fatigue, feeling cold, or weight gain. Treating the thyroid problem often brings the LDL number down on its own.

Medications. Steroids raise triglycerides and LDL. Some antipsychotic medications raise triglycerides substantially. Certain HIV medications, older diuretics, and beta-blockers can affect lipids as well. A full medication review is part of any complete evaluation, since switching or adjusting a medication sometimes solves the problem without adding a new one.

Sitting too much. Physical inactivity lowers HDL, raises triglycerides, and worsens the effects of extra calories. Its effect on your heart health is separate from, and adds to, your lipid numbers, which is why exercise helps even when weight doesn’t change much.

These causes stack on top of each other. Someone with a genetic tendency, a high-refined-carb diet, low activity, and early insulin resistance can end up with a badly abnormal lipid profile driven by all of these at once. Fixing just one usually isn’t enough, which is why a good evaluation looks at the whole picture rather than treating a single number in isolation.

Complications: What’s Really at Stake

Heart Attack and Atherosclerosis

The link between elevated cholesterol-carrying particles and heart disease is one of the most well-proven findings in medicine, backed by genetic studies, clinical trials, and decades of population data. LDL particles build up in artery walls, pull in immune cells, and form plaques that slowly narrow the coronary arteries. Stable plaques reduce blood flow and cause chest pain with exertion, a warning sign your body sometimes does give you. Unstable, cholesterol-rich plaques are more dangerous: they can rupture without warning, triggering a clot and a heart attack, even in an artery that wasn’t severely narrowed beforehand. The U.S. sees roughly 800,000 heart attacks a year. Most happen in people with risk factors that could have been found and treated ahead of time.

Stroke

Atherosclerosis isn’t limited to the heart. The arteries in your neck and brain are just as vulnerable. High cholesterol contributes to stroke two ways: through plaque rupture and clotting in the large arteries feeding the brain, and through slow, ongoing damage to the small vessels deep inside the brain itself. Stroke is the fifth leading cause of death in the U.S. and the leading cause of long-term disability, which makes catching the process early, before a stroke happens, especially valuable.

Peripheral Artery Disease

When atherosclerosis affects the arteries in your legs, the result is peripheral artery disease: poor circulation that causes pain with walking, slow-healing wounds, and in advanced cases, tissue damage and limb loss. PAD affects 8 to 10 million Americans and is a strong signal of heart and stroke risk as well, since the same process narrowing the leg arteries is very likely happening elsewhere too.

Physical Signs You Can See

Severely high cholesterol, especially familial hypercholesterolemia, can produce visible signs on the body. Xanthomas are yellowish cholesterol deposits that show up in tendons, like the Achilles tendon or the back of the hand, or on the eyelids, where they’re called xanthelasmas. Arcus senilis is a whitish ring around the edge of the cornea. Any of these findings in a patient under 45 should prompt immediate testing for FH.

Metabolic Syndrome and Diabetes Risk

The insulin-resistance lipid pattern is both a cause and an effect of broader metabolic problems. High triglycerides, low HDL, extra belly fat, and rising blood sugar together define metabolic syndrome, which raises cardiovascular risk on its own and is also a well-established warning sign for type 2 diabetes down the road. Treating the lipid piece of this puzzle can’t really be separated from treating your overall metabolic health.

Pancreatitis

This complication is specific to very high triglycerides. When triglycerides climb above 500 mg/dL, and especially above 1,000, the risk of acute pancreatitis becomes real. This type of pancreatitis can be severe, life-threatening, and it tends to come back if triglycerides aren’t brought under control. Treatment is aggressive: fibrate medications, high-dose omega-3s, and strict carbohydrate restriction.

Lp(a): The Risk Factor Most Patients Have Never Heard Of

Lipoprotein(a) is an LDL particle with an extra protein, apolipoprotein(a), attached. It’s almost entirely determined by genetics. Your diet, exercise habits, and body weight don’t change your Lp(a) level in any meaningful way. You’re born with roughly the level you’ll carry for life.

A high Lp(a), defined as 50 mg/dL or higher (or above the 75th to 80th percentile), affects about 1 in 5 people. It’s an independent risk factor for heart attack, stroke, aortic valve disease, and peripheral artery disease. It works differently than LDL: it directly damages arteries, promotes clotting, and slows the body’s ability to break clots apart.

Most patients have never been tested for a simple reason: Lp(a) isn’t part of a standard panel. It has to be ordered separately. Major lipid societies now recommend at least one Lp(a) test in every adult’s lifetime, and current guidelines support testing patients with early heart disease, a strong family history, or borderline risk where the result would change the plan.

Here’s why it matters: a patient with an LDL of 108 mg/dL, technically “near optimal,” who also has an Lp(a) of 130 mg/dL, carries much higher risk than the LDL number alone suggests. Without the test, you’re missing part of the picture.

Right now, no approved medication substantially lowers Lp(a) on its own. PCSK9 inhibitors lower it by roughly 25 to 30 percent; statins may raise it slightly. Several gene-targeted therapies are in late-stage trials and are closely watched in heart medicine. Knowing your Lp(a) may not change treatment today, but it changes the conversation: it can push your LDL target lower, support starting a statin sooner even with a borderline LDL, or simply give you the full picture to decide.

The 2026 Guidelines: What Changed

In March 2026, the ACC and AHA published an entirely new guideline, replacing the 2018 document. It’s now called the 2026 ACC/AHA Guideline on the Management of Dyslipidemia, a name change reflecting a broader focus: LDL, triglyceride-rich particles, and Lp(a) are now treated as equally important.

The core message is “earlier and lower, for longer.” Keeping LDL low over more years gives protection you can’t fully make up for by starting later. This changes how borderline and intermediate-risk patients are managed.

New risk calculator: PREVENT replaces the old formula. The old tool, the Pooled Cohort Equations, overestimated 10-year risk by 40 to 50 percent in many people. The replacement, PREVENT-ASCVD, is built for adults 30 to 79 without known heart disease and an LDL between 70 and 189 mg/dL. It estimates 10- and 30-year risk using updated categories:

10-Year ASCVD Risk	Category
< 3%	Low
3% to < 5%	Borderline
5% to < 10%	Intermediate
≥ 10%	High

Specific LDL targets are back. The 2018 guideline moved away from numeric targets. The 2026 guideline restores them, based on risk category and, for some patients, coronary calcium score:

Clinical Scenario	LDL-C Goal
Borderline or Intermediate risk	< 100 mg/dL
High risk (primary prevention)	< 70 mg/dL
Very high risk / established heart disease	< 55 mg/dL
Calcium score 1–99, below 75th percentile	< 100 mg/dL
Calcium score 100–299 or ≥ 75th percentile	< 70 mg/dL
Calcium score ≥ 1,000	< 55 mg/dL

Coronary calcium scoring now has clear targets attached. A selective CAC scan is recommended for men 40+ and women 45+ at borderline or intermediate risk, when it would change the plan. A calcium score of zero supports holding off on a statin; any detectable calcium raises how aggressively we treat.

Lp(a) testing is now recommended for every adult, at least once. The threshold is 125 nmol/L or 50 mg/dL, carrying roughly 1.4 times the long-term risk of heart attack or stroke. At 250 nmol/L or higher, the risk is at least double. Since Lp(a) is genetic and stable over time, one test in adulthood is generally enough.

ApoB’s role is more specific now. It checks leftover risk in patients who’ve already hit their LDL and non-HDL targets, especially with metabolic syndrome, diabetes, high triglycerides, or existing heart disease. It’s not a screening test for everyone, but in that group it predicts risk better than LDL alone.

Non-statin options. Ezetimibe and bempedoic acid remain solid oral add-ons. PCSK9 antibody injections suit very-high-risk patients not at goal on oral therapy, with strong outcome data. Inclisiran, an injection given twice a year, lowers LDL about as well, but outcome data proving it prevents heart attacks and strokes is still pending.

New risk-enhancing factors. Additions include South Asian and Filipino ancestry, early menopause, a history of preeclampsia or gestational diabetes, and poor sleep. Older factors, like family history of early heart disease, chronic inflammation, kidney disease, and metabolic syndrome, remain on the list.

Treatment: What the Options Actually Look Like

Once your numbers and risk profile are clear, treatment is genuinely individualized — there isn’t one “right” medication for everyone. Statins are one of several effective options, not the default or the only path, and your provider will weigh factors like your LDL-C and ApoB levels, your calculated risk score, other health conditions, and your own preferences and tolerance before recommending a starting point. If a statin isn’t the right fit for you, that doesn’t mean you’re out of options — several other medication classes work well on their own or alongside a statin.

Statins

Statins are often considered first because they have the longest track record, the most robust outcomes data, and they work for the majority of patients with minimal side effects. They lower LDL-C by blocking an enzyme (HMG-CoA reductase) the liver uses to produce cholesterol, and in doing so they’ve been shown to meaningfully reduce heart attacks and strokes across large, long-term studies. That said, statins are not the only medication that lowers cholesterol effectively, and a meaningful minority of patients experience side effects — most commonly muscle aches — that lead them to stop or switch. If you’ve had a difficult experience with statins in the past, or you’re hesitant to start one, it’s worth knowing that effective non-statin alternatives exist and are outlined below.

Non-Statin and Combination Options

For patients who are statin-intolerant, need additional LDL lowering, or simply prefer a different approach, several non-statin medications are available — and many of these work well as standalone therapy, not just as add-ons.

• Ezetimibe reduces the amount of cholesterol absorbed in the gut and can be used alone or paired with a statin for additional LDL lowering.
• Bempedoic acid works through a pathway similar to statins but is processed differently in the body, meaning it typically doesn’t cause the muscle-related side effects some patients experience with statins — making it a genuine option on its own, not just an add-on, for statin-intolerant patients.
• PCSK9 inhibitors (injectable, typically every 2–4 weeks) can lower LDL-C dramatically, often 50–60%, and are especially useful for patients with very high risk or genetically elevated cholesterol.
• Inclisiran is a newer injectable option given just twice a year that works through a different mechanism (silencing PCSK9 production) and offers a lower-maintenance path to sustained LDL reduction.

Which of these makes sense — alone, in combination, or alongside a statin — depends on your specific numbers, risk level, and how your body responds, and is a conversation worth having directly with your provider.

The bottom line: treatment isn’t one-size-fits-all, and statins work well for many people — but they’re not the only route to a healthier LDL. If cost, side effects, or hesitation about statins has held you back from treatment, there are other effective paths forward.

The Annual Physical: Your Most Important Cardiovascular Appointment

Cardiovascular risk builds up over years. One blood test, on its own, is a single snapshot. An annual physical gives you the whole timeline, and the timeline is what actually matters most.

Most heart attacks and strokes don’t come out of nowhere. They’re the endpoint of a process that was measurable, and often treatable, years earlier. But you can only see that window if someone is tracking your numbers consistently, in context, over time. A lipid result from three years ago tells you little about where you’re headed. Five years of results tells you whether your numbers are holding steady, getting worse, or improving with treatment. The annual physical is the one place in primary care where that full, longitudinal picture comes together.

At most offices, the visit goes like this: a lipid panel is ordered, and if LDL falls under a certain number, the visit moves on. “A little high. Watch your diet.” You leave with no risk score, no talk of ApoB or Lp(a), and no real sense of what the numbers mean given your age, family history, and metabolic health. That approach misses exactly the patients it most needs to catch: the ones who look fine on paper but carry a more complicated risk underneath.

At Altitude, your lipid evaluation is part of a full cardiometabolic checkup. We look at the complete panel alongside blood pressure, fasting glucose, HbA1c when needed, weight, waist size, family history, medications, and lifestyle. We run the PREVENT-ASCVD calculator and talk through what the result actually means for you, right now. And we track how your numbers move year over year, not just whether they’ve crossed a line today.

For patients with metabolic risk factors or signs of insulin resistance, we add ApoB. For patients with early heart disease, a strong family history, or borderline risk where the treatment decision genuinely isn’t clear, we order Lp(a). These aren’t specialty referrals or add-ons meant to run up a bill. They’re a normal part of a thorough visit, used selectively, when the clinical picture calls for them.

Carotid Ultrasound: A Direct Look at Your Arteries

Lab tests tell you about the factors driving your risk. Imaging tells you whether that risk has already shown up in your artery walls. Both matter, and they answer different questions.

Carotid ultrasound uses sound waves to picture the carotid arteries, the two major vessels in your neck that supply blood to your brain. The test itself is simple and painless: you lie down, a technician applies gel to your neck, and a handheld probe captures images of the artery walls. There’s no needle, no radiation, and no preparation needed beforehand. Most exams take 20 to 30 minutes.

At Altitude, we perform a combined evaluation that looks at both plaque and intima-media thickness (IMT) in the same exam, because together they give a fuller picture than either alone. Plaque shows whether atherosclerosis has already formed a visible buildup on the artery wall. IMT shows how thick the artery wall itself is, which can reveal early changes even before a distinct plaque has formed. Looking at both together means we’re not just checking for a yes-or-no finding of disease. We’re tracking the artery wall’s condition along a continuum, which gives us an earlier and more complete signal than either measurement would on its own. Finding either plaque or early thickening in a patient with borderline lipid numbers can meaningfully change how we think about their risk.

Carotid ultrasound has real advantages beyond what it shows. There’s no radiation, which makes it a good option for younger patients or anyone we want to re-check periodically without cumulative exposure concerns. It doesn’t require the specialized CT scanner used for coronary calcium scoring, so it’s more accessible and can often be scheduled quickly. And because it images the neck arteries directly, it adds stroke-risk information that a calcium score, which focuses on the heart, doesn’t capture on its own.

We use carotid ultrasound most often when risk is genuinely uncertain: a borderline PREVENT-ASCVD score, near-optimal LDL, and a family history of early stroke, for example. In that setting, a direct look at the artery wall can be the deciding piece of information that shapes whether we start treatment now or continue watching closely.

This is a decision made with you, not a checklist applied to everyone. The annual physical is where we decide, together, which additional tests fit your situation. If your last cholesterol conversation ended with “watch your diet” and nothing else, there’s more worth discussing.

What You Can Do Starting Today

• Schedule your annual physical. A lipid number without context is a starting point, not a full answer. An annual visit gives you the framework to understand your numbers and where you’re headed. Schedule here.
• Know your actual numbers. Get a copy of your lab results: LDL, HDL, triglycerides, non-HDL, and ApoB or Lp(a) if ordered. “Normal” isn’t a result. A number is a result.
• Cut back on refined carbs and added sugar. This is the single best diet change for lowering triglycerides and improving your TG/HDL ratio, especially with the insulin-resistance pattern.
• Swap saturated fat for unsaturated fat. Replace red meat, full-fat dairy, and tropical oils with olive oil, avocado, nuts, and fatty fish. This lowers LDL, and the effect adds up over years.
• Add soluble fiber. Oats, beans, legumes, psyllium husk, and certain fruits bind cholesterol in your gut. An extra 5 to 10 grams a day can lower LDL by 3 to 5 percent.
• Move consistently. Regular aerobic exercise raises HDL, lowers triglycerides, and improves insulin sensitivity. Aim for 150 minutes a week of moderate activity, roughly a 30-minute walk most days.
• Ask about Lp(a) if early heart disease runs in your family. If a parent or sibling had a heart attack or stroke before 60, ask about testing. It’s one blood draw that can change how we think about your risk.
• Don’t treat “borderline” as a green light to wait. It’s your best window for action, before full hyperlipidemia sets in. Use the information while you have the advantage.

The Bottom Line

Hyperlipidemia is common, silent, and serious. The standard approach, a basic lipid panel checked for obvious red flags, misses risk in a real share of patients. A complete evaluation looks beyond LDL, HDL, and triglycerides to include non-HDL cholesterol, ApoB when clinically useful, Lp(a) for patients with the right risk factors, and the TG/HDL ratio as a window into metabolic health. None of this is exotic. It’s available, it’s meaningful, and most patients have simply never had it ordered.

The borderline zone is not a safe zone. Patients with an LDL between 100 and 129, a high Lp(a), or an insulin-resistance pattern carry real risk that a standard panel routinely underestimates. This is the window where action pays off most, before atherosclerosis has advanced, before you cross an official threshold, and long before any symptom shows up. There’s no symptom to wait for. That’s exactly the problem.

At Altitude, a lipid evaluation is a conversation about where your heart health is headed. We use the data that actually matters, read it in full context, and build a plan around your real risk and your goals. If it’s been a while since your last comprehensive lipid evaluation, or you’ve been told your numbers are “fine” without seeing the full picture, the next step is an appointment. Schedule online here.

For more on cholesterol, cardiometabolic health, and preventive care, visit the Altitude Medicine blog.

References

1. Blumenthal RS, Morris PB, Gaudino M, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia. J Am Coll Cardiol. 2026;87(19):2624-2757. doi:10.1016/j.jacc.2025.11.016
2. Tsimikas S. A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies. J Am Coll Cardiol. 2017;69(6):692-711. doi:10.1016/j.jacc.2016.11.042
3. Sniderman AD, Thanassoulis G, Glavinovic T, et al. Apolipoprotein B Particles and Cardiovascular Disease: A Narrative Review. JAMA Cardiol. 2019;4(12):1287-1295. doi:10.1001/jamacardio.2019.3780
4. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017;376(18):1713-1722. doi:10.1056/NEJMoa1615664
5. Ray KK, Wright RS, Kallend D, et al. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. N Engl J Med. 2020;382(16):1507-1519. doi:10.1056/NEJMoa1912387
6. Nordestgaard BG, Chapman MJ, Humphries SE, et al. Familial Hypercholesterolaemia Is Underdiagnosed and Undertreated in the General Population: Guidance for Clinicians to Prevent Coronary Heart Disease. Eur Heart J. 2013;34(45):3478-3490. doi:10.1093/eurheartj/eht273
7. Catapano AL, Graham I, De Backer G, et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J. 2016;37(39):2999-3058. doi:10.1093/eurheartj/ehw272
8. Gepner AD, Korcarz CE, Colangelo LA, et al. Carotid Intima-Media Thickness and Plaque for Cardiovascular Risk Assessment: A Report From the American Society of Echocardiography. J Am Soc Echocardiogr. 2020;33(8):913-933. doi:10.1016/j.echo.2020.04.021
9. Despres JP, Lemieux I. Abdominal Obesity and Metabolic Syndrome. Nature. 2006;444(7121):881-887. doi:10.1038/nature05488
10. Falk E, Shah PK, Fuster V. Coronary Plaque Disruption. Circulation. 1995;92(3):657-671. doi:10.1161/01.CIR.92.3.657

Graphic and Interactive Placements Summary

#	Location in Article	Type	Description
1	After Diagnostic Table (Section: The Numbers)	Interactive spectrum bar / risk category visualizer	Five horizontal spectrum bars (LDL-C, ApoB, Lp(a), TG/HDL, Non-HDL-C), color-coded green-yellow-red. Interactive: user enters lab values; each bar populates with a pin showing result placement. Output summary text. Scheduling CTA. No PHI stored.
2	After Treatment section (before Annual Physical)	Static infographic / treatment decision flowchart	Three-column flowchart: risk inputs (LDL, ApoB, Lp(a), ASCVD score, DM, prior events, FH) to risk tier (low/borderline/intermediate/high/very high) to treatment pathway (lifestyle only; + statin; + ezetimibe; + PCSK9i/inclisiran). Static, no user inputs required.
3	Before 2026 Guidelines (standalone Lp(a) section)	Awareness callout panel / interactive “Have You Been Tested?” widget	Static: three key Lp(a) statistics with brief explanation and scheduling CTA. Interactive: three yes/no prompts (prior CVD with normal cholesterol; family history of early heart disease; prior Lp(a) test). Output: personalized recommendation to discuss testing, with scheduling link. No PHI stored.